NCT03220724 - Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

August 22, 2017

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions

HIV Infections

Interventions

BIOLOGICAL

CH505TF

Administered by intramuscular (IM) injection in the thigh

BIOLOGICAL

CH505w53

Administered by IM injection in the thigh

BIOLOGICAL

CH505w78

Administered by IM injection in the thigh

BIOLOGICAL

CH505 M5

Administered by IM injection in the thigh

BIOLOGICAL

GLA-SE adjuvant

Admixed with all CH505 gp120 proteins

BIOLOGICAL

Placebo

Administered by IM injection in the thigh

Trial Locations (8)

10065

New York Blood Center CRS, New York

14642

University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester

19104

Penn Prevention CRS, Philadelphia

35294

Alabama CRS, Birmingham

94102

Bridge HIV CRS, San Francisco

98104

Seattle Vaccine and Prevention CRS, Seattle

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

10032-3732

Columbia P&S CRS, New York

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH